Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus FLOT in Gastric/GEJ Adenocarcinoma
NCT04341857Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2019
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete response rate. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04341857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341857.